|
|
| |
| Articles
by
Colleen E. Jackson |
Total Records (
2 ) for
Colleen E. Jackson |
|
 |
| |
|
| |
Peter J. Snyder
,
Kathryn V. Papp
,
Jennifer Bartkowiak
,
Colleen E. Jackson
and
Rachelle S. Doody
|
| |
A major barrier to progress in Alzheimer's disease treatment research is the increasingly difficult task of recruiting elderly participants into clinical trials. We conducted an anonymous online survey of 676 adults (average age, 50 years) to examine perceived trust in different components of our healthcare-delivery and clinical-research systems, as well as willingness to participate in clinical trials. Respondents indicated the greatest amount of trust in family members, followed by family physicians. Only 3% of respondents `completely` trusted clinical researchers, whereas 62% of respondents trusted them `somewhat` to care for them during the course of a clinical trial. Trust in clinical researchers was modestly negatively correlated with income (r = −0.165, P < .001), but was not significantly related to sex, race, or education. Respondents indicated the least amount of trust in industry sponsors, followed by regulatory authorities. |
|
| |
|
| |
Peter J. Snyder
,
Colleen E. Jackson
,
Ronald C. Petersen
,
Ara S. Khachaturian
,
Jeffrey Kaye
,
Marilyn S. Albert
and
Sandra Weintraub
|
| |
The demand for rapidly administered, sensitive, and reliable cognitive assessments that are specifically designed for identifying individuals in the earliest stages of cognitive decline (and to measure subtle change over time) has escalated as the emphasis in Alzheimer‘s disease clinical research has shifted from clinical diagnosis and treatment toward the goal of developing presymptomatic neuroprotective therapies. To meet these changing clinical requirements, cognitive measures or tailored batteries of tests must be validated and determined to be fit-for-use for the discrimination between cognitively healthy individuals and persons who are experiencing very subtle cognitive changes that likely signal the emergence of early mild cognitive impairment. We sought to collect and review data systematically from a wide variety of (mostly computer-administered) cognitive measures, all of which are currently marketed or distributed with the claims that these instruments are sensitive and reliable for the early identification of disease or, if untested for this purpose, are promising tools based on other variables. The survey responses for 16 measures/batteries are presented in brief in this review; full survey responses and summary tables are archived and publicly available on the Campaign to Prevent Alzheimer‘s Disease by 2020 Web site (http://pad2020.org). A decision tree diagram highlighting critical decision points for selecting measures to meet varying clinical trials requirements has also been provided. Ultimately, the survey questionnaire, framework, and decision guidelines provided in this review should remain as useful aids for the evaluation of any new or updated sets of instruments in the years to come. |
|
|
|
|
| |
|
